EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stake Boosted by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC increased its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 35.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,990 shares of the company’s stock after buying an additional 4,450 shares during the period. Cyndeo Wealth Partners LLC’s holdings in EyePoint Pharmaceuticals were worth $127,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. JPMorgan Chase & Co. lifted its stake in shares of EyePoint Pharmaceuticals by 1,171.3% in the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock worth $2,970,000 after buying an additional 342,516 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 9.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after purchasing an additional 362,399 shares in the last quarter. Geode Capital Management LLC boosted its stake in EyePoint Pharmaceuticals by 16.1% during the third quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock worth $9,583,000 after buying an additional 166,699 shares in the last quarter. Barclays PLC boosted its position in shares of EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after acquiring an additional 197,033 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of EyePoint Pharmaceuticals by 59.4% in the 3rd quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock valued at $1,372,000 after purchasing an additional 64,008 shares during the period. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Down 3.3 %

NASDAQ EYPT opened at $8.53 on Monday. The company has a market capitalization of $582.17 million, a P/E ratio of -4.27 and a beta of 1.49. EyePoint Pharmaceuticals, Inc. has a 12-month low of $6.90 and a 12-month high of $30.99. The firm has a 50-day moving average price of $8.16 and a two-hundred day moving average price of $8.95.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.06). The firm had revenue of $10.52 million for the quarter, compared to analyst estimates of $12.35 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Equities analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analyst Weigh In

EYPT has been the subject of a number of recent analyst reports. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price for the company. Chardan Capital boosted their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Scotiabank started coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Finally, Robert W. Baird reduced their price objective on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.